HIV-associated neurocognitive disorders

Neurology: Clinical Practice

Volumn 5, Issue 3, 2015, Pages 224-231

  Rumbaugh, Jeffrey A ^a,b   Tyor, William ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ATLANTA VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ATAZANAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; FOSAMPRENAVIR; INDINAVIR; LAMIVUDINE PLUS STAVUDINE; LOPINAVIR; MARAVIROC; NELFINAVIR; NEVIRAPINE; RALTEGRAVIR; RITONAVIR PLUS SAQUINAVIR; TENOFOVIR; TIPRANAVIR; ZALCITABINE; ZIDOVUDINE;

AGING; ANTIVIRAL THERAPY; ARTICLE; BLOOD BRAIN BARRIER; CLADISTICS; COGNITIVE DEFECT; COMBINED ANTIRETROVIRAL THERAPY; COMORBIDITY; DRUG ABUSE; HEPATITIS C; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NEUROPATHOLOGY; PREVALENCE; PRIORITY JOURNAL; SCORING SYSTEM;

EID: 84930713724     PISSN: 21630402     EISSN: 21630933     Source Type: Journal    
DOI: 10.1212/CPJ.0000000000000117     Document Type: Article

References (20)

1. Sacktor N, McDermott MP, Marder K, et al. HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol 2002;8:136-142.
2. Navia BA, Jordan BD, Price RW. The AIDS dementia complex: I. Clinical features. Ann Neurol 1986;19:517-524.
3. Janssen RS, Cornblath DR, Epstein LG. Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type 1 (HIV-1) infection. Report of a Working Group of the American Academy of Neurology AIDS Task Force. Neurology 1991;41: 778-785.
4. Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007;69:1789-1799.
5. Everall I, Vaida F, Khanlou N, et al. Cliniconeuropathologic correlates of human immunodeficiency virus in the era of antiretroviral therapy. J Neurovirol 2009;15:360-370.
6. Sacktor N, Nakasujja N, Skolasky R, et al. Antiretroviral therapy improves cognitive impairment in HIV1 individuals in sub-Saharan Africa. Neurology 2006;67:311-314.
7. Nath A, Schiess N, Venkatesan A, Rumbaugh J, Sacktor N, McArthur J. Evolution of HIV dementia with HIV infection. Int Rev Psychiatry 2008;20:25-31.
8. Letendre S, Marquie-Beck J, Capparelli E, et al. Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008;65: 65-70.
9. Cysique LA, Maruff P, Brew BJ. Antiretroviral therapy in HIV infection: are neurologically active drugs important? Arch Neurol 2004;61:1699-1704.
10. Ellis RJ, Moore DJ, Childers ME, et al. Progression to neuropsychological impairment in human immunodeficiency virus infection predicted by elevated cerebrospinal fluid levels of human immunodeficiency virus RNA. Arch Neurol 2002;59:923-928.
11. Letendre SL, McCutchan JA, Childers ME, et al. Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders. Ann Neurol 2004;56:416-423.
12. Joseph J, Achim CL, Boivin MJ, et al. Global NeuroAIDS roundtable. J Neurovirol 2013;19: 1-9.
13. Rao VR, Neogi U, Talboom JS, et al. Clade C HIV-1 isolates circulating in Southern Africa exhibit a greater frequency of dicysteine motif-containing Tat variants than those in Southeast Asia and cause increased neurovirulence. Retrovirology 2013;10:61.
14. Glass JD, Wesselingh SL, Selnes OA, McArthur JC. Clinical-neuropathologic correlation in HIVassociated dementia. Neurology 1993;43:2230-2237.
15. Tyor WR, Fritz-French C, Nath A. Effect of HIV clade differences on the onset and severity of HIVassociated neurocognitive disorders. J Neurovirol 2013;19:515-522.
16. Becker JT, Kingsley L, Mullen J, et al. Vascular risk factors, HIV serostatus, and cognitive dysfunction in gay and bisexual men. Neurology 2009;73:1292-1299.
17. Letendre S, Paulino AD, Rockenstein E, et al. Pathogenesis of hepatitis C virus coinfection in the brains of patients infected with HIV. J Infect Dis 2007;196:361-370.
18. Vivithanaporn P, Nelles K, Deblock L, Newman SC, Gill MJ, Power C. Hepatitis C virus coinfection increases neurocognitive impairment severity and risk of death in treated HIV/AIDS. J Neurol Sci 2012;312:45-51.
19. Nath A. Human immunodeficiency virus-associated neurocognitive disorder: pathophysiology in relation to drug addiction. Ann N Y Acad Sci 2010;1187:122-128.
20. Tyor WR, Middaugh LD. Do alcohol and cocaine abuse alter the course of HIV-associated dementia complex? J Leukoc Biol 1999;65:475-481.